Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
NCT07066982
DNA Virus Infections, Hemic and Lymphatic Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT Number: NCT04122872
GISAR has an open and modular setup. It is sought to include as many German sarcoma and CS patients (i.e. sarcoma and CS patients treated in Germany) in the registry as possible. A basic data set should be collected on every included patient). In order to adress specific scientific questions, additionally detailed data can be collected in defined patient groups (e.g. effectiveness / adverse effects of systemic therapies in defined situations) within the context of sub-project add-on modules. This data collection can be prospective or retrospective depending on the sub-project
Interested in participating?
Request Info18 year and older
All sexes
Observational
Universitätsklinikum Tübingen, Tübingen, Baden-Wurttemberg, Germany
Sarcomas are rare malignant tumors that affect people of all ages. They can be divided into different subtypes yet having more than 80 different forms of soft tissue sarcomas only. In these terms, it is not remarkable that this high number of subtypes is accompanied by various treatment strategies, often representing multimodal treatments.
In addition, in a growing amount of patients tumors are diagnosed, whose malignant cells have histological, cytological, or molecular properties of both epithelial tumors ("carcinoma") and mesenchymal tumors ("sarcoma").
Such "mixed" sarcomatoid/epithelial tumors ("CS") are categorized as carcinoma considering their epithelial origin. But in most cases, CS seem to be more aggressive, than other carcinomas with the same origin; often they are characterized by rapid growth, invasion, disease recurrence and metastases.
Due to the rarity of CS, only limited information is available about their clinical course and best therapeutic approaches. Because of these uncertainties and the sarcoma-component of the tumors, several CS-patients are referred to sarcomacenters. As many experiences with single CS-cases as possible should be collected and evaluated to better understand the different CS-forms.
Due to the complexity of diagnosis and therapy of sarcomas and of CS it is of high relevance to depict the current treatment landscape and the effects and course of different treatment options to illuminate the best option for each specific patient. This is compassed by this registry, as it aims to collect information and data on treatment and outcome of most of future German sarcoma cases along with retrospective data collection to achieve a most comprehensive data set as well as the possibility to identify alterations / trends in the procedures used for sarcoma diagnosis and therapy over time.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
Generation of epidemiological data
Time frame: 1 year
Generation of epidemiological data
Time frame: 1 year
Generation of epidemiological data
Contact information is provided by the study sponsor or research team.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Other
Acronym: GISAR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07066982
DNA Virus Infections, Hemic and Lymphatic Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT06637007
Neoplasms, Neoplasms by Histologic Type
Taiyuan, Shanxi, China
View Trial DetailsNCT06074692
Neoplasms, Neoplasms by Histologic Type
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT04028479
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Idaho Falls, Idaho, United States
View Trial Details